Evidence map›Paper›PMID 31473980›Full record

ReviewCNS drugs2019

Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

Federico Carbone, Atbin Djamshidian, Klaus Seppi, Werner Poewe

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it, 175 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.Movement disorders : official journal of the Movement Disorder Society · 2022
    Trial
  6. Article
  7. Review
  8. Review
  9. Cardiovascular pharmacology of dopaminergic agents in humans: a review.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Federico CarboneDepartment of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.
Atbin DjamshidianDepartment of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.
Klaus SeppiDepartment of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.
Werner PoeweDepartment of Neurology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria. werner.poewe@i-med.ac.at.
Innsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D

Indexed as

AnimalsAntiparkinson AgentsApomorphineClinical Trials as TopicDopamineHumansParkinson DiseaseAntiparkinson AgentsApomorphineDopamine

Identifiers

PMID31473980
PMCPMC6776563
OpenAlexW2971102518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.